News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
737,785 Results
Type
Article (43659)
Company Profile (473)
Press Release (693641)
Multimedia
Podcasts (122)
Webinars (20)
Section
Business (209306)
Career Advice (2038)
Deals (36151)
Drug Delivery (119)
Drug Development (83961)
Employer Resources (174)
FDA (16685)
Job Trends (15185)
News (354128)
Policy (33276)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2655)
Accelerated approval (34)
Adcomms (28)
Allergies (141)
Alliances (51111)
ALS (177)
Alzheimer's disease (1721)
Antibody-drug conjugate (ADC) (325)
Approvals (16922)
Artificial intelligence (536)
Autoimmune disease (154)
Automation (37)
Bankruptcy (373)
Best Places to Work (11840)
BIOSECURE Act (20)
Biosimilars (191)
Biotechnology (331)
Bladder cancer (162)
Brain cancer (59)
Breast cancer (646)
Cancer (4898)
Cardiovascular disease (414)
Career advice (1723)
Career pathing (37)
CAR-T (290)
CDC (46)
Celiac Disease (2)
Cell therapy (771)
Cervical cancer (36)
Clinical research (71388)
Collaboration (1774)
Company closure (4)
Compensation (1169)
Complete response letters (62)
COVID-19 (2769)
CRISPR (96)
C-suite (860)
Cystic fibrosis (152)
Data (6267)
Decentralized trials (2)
Denatured (39)
Depression (141)
Diabetes (502)
Diagnostics (6734)
Digital health (45)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (259)
Drug pricing (196)
Drug shortages (29)
Duchenne muscular dystrophy (242)
Earnings (91329)
Editorial (59)
Employer branding (21)
Employer resources (152)
Events (120941)
Executive appointments (994)
FDA (19816)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1517)
Gene editing (211)
Generative AI (44)
Gene therapy (640)
GLP-1 (1006)
Government (4754)
Grass and pollen (6)
Guidances (384)
Healthcare (19202)
HIV (57)
Huntington's disease (46)
IgA nephropathy (85)
Immunology and inflammation (270)
Immuno-oncology (59)
Indications (105)
Infectious disease (3035)
Inflammatory bowel disease (197)
Inflation Reduction Act (17)
Influenza (114)
Intellectual property (247)
Interviews (315)
IPO (16929)
IRA (52)
Job creations (3712)
Job search strategy (1439)
JPM (65)
Kidney cancer (15)
Labor market (83)
Layoffs (580)
Leadership (32)
Legal (8025)
Liver cancer (93)
Longevity (14)
Lung cancer (662)
Lymphoma (378)
Machine learning (43)
Management (59)
Manufacturing (798)
MASH (169)
Medical device (13909)
Medtech (13961)
Mergers & acquisitions (20291)
Metabolic disorders (1309)
Multiple sclerosis (165)
NASH (19)
Neurodegenerative disease (336)
Neuropsychiatric disorders (95)
Neuroscience (3002)
Neurotech (1)
NextGen: Class of 2026 (6770)
Non-profit (4580)
Now hiring (65)
Obesity (626)
Opinion (281)
Ovarian cancer (167)
Pain (204)
Pancreatic cancer (229)
Parkinson's disease (294)
Partnered (34)
Patents (493)
Patient recruitment (489)
Peanut (56)
People (60269)
Pharmaceutical (85)
Pharmacy benefit managers (30)
Phase 1 (22456)
Phase 2 (31475)
Phase 3 (23271)
Pipeline (5194)
Policy (294)
Postmarket research (2602)
Preclinical (9600)
Press Release (67)
Prostate cancer (243)
Psychedelics (55)
Radiopharmaceuticals (296)
Rare diseases (881)
Real estate (6064)
Recruiting (70)
Regulatory (24959)
Reports (51)
Research institute (2482)
Resumes & cover letters (353)
Rett syndrome (27)
RNA editing (21)
RSV (76)
Schizophrenia (154)
Series A (254)
Series B (197)
Service/supplier (11)
Sickle cell disease (103)
Special edition (26)
Spinal muscular atrophy (162)
Sponsored (42)
Startups (3803)
State (2)
Stomach cancer (18)
Supply chain (106)
Tariffs (85)
The Weekly (81)
Vaccines (1017)
Venture capital (93)
Weight loss (406)
Women's health (89)
Worklife (19)
Date
Today (79)
Last 7 days (588)
Last 30 days (2107)
Last 365 days (30692)
2026 (3010)
2025 (31063)
2024 (36297)
2023 (41014)
2022 (52277)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33023)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (754)
Alabama (89)
Alaska (7)
Arizona (314)
Arkansas (14)
Asia (40678)
Australia (6759)
California (11394)
Canada (3280)
China (1131)
Colorado (482)
Connecticut (490)
Delaware (335)
Europe (89149)
Florida (1673)
Georgia (357)
Hawaii (3)
Idaho (61)
Illinois (878)
India (63)
Indiana (521)
Iowa (24)
Japan (428)
Kansas (129)
Kentucky (40)
Louisiana (27)
Maine (72)
Maryland (1396)
Massachusetts (8292)
Michigan (322)
Minnesota (635)
Mississippi (5)
Missouri (129)
Montana (33)
Nebraska (28)
Nevada (121)
New Hampshire (83)
New Jersey (3033)
New Mexico (31)
New York (2985)
North Carolina (1520)
North Dakota (9)
Northern California (5530)
Ohio (335)
Oklahoma (21)
Oregon (45)
Pennsylvania (2286)
Puerto Rico (22)
Rhode Island (48)
South America (1121)
South Carolina (65)
South Dakota (1)
Southern California (4419)
Tennessee (173)
Texas (1754)
United States (40548)
Utah (339)
Vermont (1)
Virginia (264)
Washington D.C. (82)
Washington State (951)
West Virginia (4)
Wisconsin (112)
Wyoming (2)
737,785 Results for "atossa therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy
January 19, 2026
·
5 min read
Press Releases
Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program
February 5, 2026
·
6 min read
Press Releases
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy
December 12, 2025
·
7 min read
Press Releases
Atossa Therapeutics to Present at the Maxim Growth Summit 2025
October 16, 2025
·
2 min read
Press Releases
Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category
December 18, 2025
·
4 min read
Press Releases
Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum
December 4, 2025
·
6 min read
Press Releases
Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
November 13, 2025
·
19 min read
Press Releases
Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium
December 16, 2025
·
7 min read
Press Releases
Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen
December 10, 2025
·
5 min read
Press Releases
Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium
November 7, 2025
·
2 min read
1 of 73,779
Next
